Infinity Licenses Intellikine’s Oral PI3K Therapies for Oncology and Inflammatory Diseases

By Heather Cartwright

Pharma Deals Review: Vol 2010 Issue 7 (Table of Contents)

Published: 13 Sep-2010

DOI: 10.3833/pdr.v2010.i7.1372     ISSN: 1756-7874

Section: Licensing



Infinity Pharmaceuticals has in-licensed global rights to Intellikine’s portfolio of phosphoinositide 3-kinase (PI3K)  inhibitors for inflammatory diseases and oncology indications in a US$488...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details